NCT05052528
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Stopped Trial status changed: Active, Not Recruiting → Suspended Sponsor's reason: Pending IRB review.
Notable Eligibility criteria expanded, about 11 words Show 5 more changesShow less
- Primary endpoints: details revised at 1 of 5 entries
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 5 of 6 entries
- Study description revised
- Site details revised
Notable Lead sponsor: Mehrdad Abedi, MD to University of California, Davisv4 Show 4 more changesShow less
- Primary completion date: May 15, 2025 to May 15, 2027
- Eligibility criteria expanded, about 109 words
- Study completion date: Dec 15, 2025 to Dec 15, 2027
- Site contact updated
- Notable Primary completion date: Aug 15, 2024 to May 15, 2025
- Study completion date: Feb 15, 2025 to Dec 15, 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 30, 2021 to Sep 17, 2021
- Site details revised
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Patients receive fludarabine phosphate IV over 30 minutes daily and cyclophosphamide IV over 60 minutes daily on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on days -5 to -3. Patients also receive CD19 CAR T cells IV on day 0.
Patients receive fludarabine phosphate IV over 30 minutes daily on days -3 to -5 and cyclophosphamide IV over 60 minutes daily on day -5. Patients also receive CD19 CAR T cells IV on day 0.
Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -3, and cyclophosphamide IV over 60 minutes on day -5. Patients also receive CD19 CAR T cells IV on day 0.
Patients receive fludarabine phosphate IV over 30 minutes daily on days -5 to -1 and cyclophosphamide IV over 60 minutes daily on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
Patients receive rituximab IV on day -5, fludarabine phosphate IV over 30 minutes daily on days -5 to -1, and cyclophosphamide IV over 60 minutes on days -5 and -4. Patients also receive CD19 CAR T cells IV on day 0.
Biologicals: Chimeric Antigen Receptor T-Cell Therapy, Rituximab
Drugs: Cyclophosphamide, Fludarabine Phosphate
Sites
1 site in 1 country
- University of California Davis Comprehensive Cancer CenterSacramento, California, United States